Clinical Trials
15 trialsNCT05456191 2026-05-27
ASC4START
Novartis
Phase 3 Active not recruiting
NCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT00644878 2021-08-18
MACS0254
Novartis
Phase 2 Terminated
NCT00980018 2021-07-01
MACS0999
Novartis
Phase 4 Completed
NCT01844765 2021-04-22
DIALOG
Novartis
Phase 2 Completed
NCT00471497 2020-11-18
ENESTnd
Novartis
Phase 3 Completed
NCT02272777 2019-08-19
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
Novartis
Phase 3 Completed
NCT02709083 2018-11-02
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Emory University
Phase 2 Terminated
NCT02108951 2017-10-27
ENESTswift
Novartis
Phase 3 Terminated
NCT01061177 2017-02-24
'MACS1252
Novartis
Phase 4 Completed
NCT00760877 2016-11-08
Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
Novartis
Phase 3 Completed
NCT01227577 2016-02-08
MACS1428
Novartis
Phase 4 Completed
NCT00802841 2015-11-16
LASOR
Novartis
Phase 3 Completed
NCT00519090 2011-11-07
ENEST
Novartis
Phase 3 Terminated